Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R

The New England journal of medicine1 Nov 2007Cited by 569 (Europe PMC)

PMID18003959DOI10.1056/nejmoa071408PepBankPUB-18003959

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, lumbar spine BMD increased more with teriparatide than alendronate, with a significant difference by 6 months.
In plain wordsTeriparatide increased spine bone density more than alendronate in glucocorticoid-induced osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 428
Comparator
Alendronate 10 mg daily
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Measurements
Lumbar spine BMD change
7.2%
teriparatide
Lumbar spine BMD change
3.4%
alendronate
Source sentences
Summary
At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A significant difference between the groups was reached by 6 months (P<0.001).
Summary · context
In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more).
Summary · context
A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily.
Report a problemFND-1800395901
02HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, total hip BMD increased more with teriparatide than alendronate at 12 months.
In plain wordsTeriparatide increased hip bone density more than alendronate in glucocorticoid-induced osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD
Study
n = 428
Comparator
Alendronate 10 mg daily
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
At 12 months, bone mineral density at the total hip had increased more in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more).
Summary · context
A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily.
Report a problemFND-1800395902
03HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, fewer new vertebral fractures occurred with teriparatide than alendronate.
In plain wordsTeriparatide produced fewer new vertebral fractures than alendronate in glucocorticoid-induced osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNew vertebral fractures
Study
n = 428
Comparator
Alendronate 10 mg daily
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Measurements
New vertebral fractures
0.6%
teriparatide
New vertebral fractures
6.1%
alendronate
Source sentences
Summary
Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004);
2 context sentences(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more).
Summary · context
A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily.
Report a problemFND-1800395903
04HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, nonvertebral fracture incidence was similar with teriparatide and alendronate.
In plain wordsNonvertebral fracture rates were similar with teriparatide and alendronate in glucocorticoid-induced osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fractures
Study
n = 428
Comparator
Alendronate 10 mg daily
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Measurements
Nonvertebral fractures
5.6%
teriparatide
Nonvertebral fractures
3.7%
alendronate
Source sentences
Summary
the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36).
2 context sentences(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more).
Summary · context
A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily.
Report a problemFND-1800395904
05HumanRandomized controlled trialSafety outcome
In glucocorticoid-induced osteoporosis, more teriparatide-treated patients had elevated serum calcium than alendronate-treated patients.
In plain wordsHigh blood calcium occurred more often with teriparatide than alendronate in glucocorticoid-induced osteoporosis.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseElevated serum calcium
Study
n = 428
Comparator
Alendronate 10 mg daily
Analysis
Secondary
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 microg once daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.
2 context sentences(design, population, supporting numbers)
Summary · context
In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more).
Summary · context
A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily.
Report a problemFND-1800395905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00051558

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Eli Lilly and Companyn = 428Nov 2002 to Jan 2008

Osteoporosis

Trial page ClinicalTrials.govUpdated 12 Mar 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.